Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 209733-13-1 | MDL No. : | MFCD08752687 |
Formula : | C7H12ClN3S | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BIHQYKGSYPXHRN-UHFFFAOYSA-N |
M.W : | 205.71 | Pubchem ID : | 23467106 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 5 |
Fraction Csp3 : | 0.57 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 60.44 |
TPSA : | 56.4 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.55 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 1.41 |
Log Po/w (WLOGP) : | 0.59 |
Log Po/w (MLOGP) : | 0.39 |
Log Po/w (SILICOS-IT) : | 1.91 |
Consensus Log Po/w : | 0.86 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.25 |
Solubility : | 1.17 mg/ml ; 0.00568 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.2 |
Solubility : | 1.3 mg/ml ; 0.00633 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.78 |
Solubility : | 3.37 mg/ml ; 0.0164 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.61 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; | (1S,2S)-4-Oxo-2-(thiophene-3-yl)cyclohexanecarboxylic acid 5 (124 mg, 0.55 mmol) and 2-(piperazin-1-yl)-1H-benzimidazole hydrochloride (127 mg, 0.46 mmol) were dissolved in tetrahydrofuran (7.60 mL), and HOBt (106 mg, 0.69 mmol) was added followed by diisopropyl ethyl amine (120 μL, 0.69 mmol) and PS-carbodimide (1.24 g, 1.38 mmol). The reaction mixture was put in a shaker at rt overnight. Upon completion, PS-trisamine (674 mg, 2.30 mmol) was added, and the resulting mixture was further shaken at rt for 2 h. Filtration of the resins followed by evaporation of the solvent afforded crude (3S,4S)-4-[4-(1H-benzimidazol-2-yl)piperazin-1-yl]carbonyl}-3-(thiophen-3-yl)cyclohexanone, which was used directly in the next step without further purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine / tetrahydrofuran / 20 °C 2: acetic acid / methanol; 1,2-dichloro-ethane / 20 - 55 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
57.1% | Stage #1: 2-(piperazin-1-yl)thiazole hydrochloride; 1,3-dimethyl-7-(3-methylbenzyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purine-8-carbaldehyde With triethylamine In dichloromethane at 20℃; Stage #2: With sodium tris(acetoxy)borohydride In dichloromethane at 20℃; for 3h; | 45 Example 45. l,3-dimethyl-7-(3-methylbenzyl)-8-((4-(thiazol-2-yl)piperazin-l-yl)methyl)-lH- e (Cpd. 10) Example 45. l,3-dimethyl-7-(3-methylbenzyl)-8-((4-(thiazol-2-yl)piperazin-l-yl)methyl)-lH- e (Cpd. 10) To l,3-dimethyl-7-(3-methylbenzyl)-2,6-dioxo-2,3,6,7-tetrahydro-lH-purine-8-carbaldehyde (31.2 mg, 0.1 mmol) and 2-(piperazin-l-yl)thiazole, HQ (41.1 mg, 0.200 mmol) was added CH2C12 (Volume: 2 mL) and then Et3N (0.028 mL, 0.2 mmol) at rt. The mixture was stirred for 3-5 min and sodium triacetoxyborohydride (127 mg, 0.600 mmol) was added. The mixture was stirred at rt for 3 h and was poured into CH2Cl2/Na2C03(aq) (3 mL/3 mL). The aqueous layer was extracted with CH2C12 (3 mL x 2). The combined organic layer was dried (Na2S04) and filtered. After removal of solvent, the crude product was purified by silica gel chromatography using 50-100% EtOAc/hexane as the eluent to give l,3-dimethyl-7-(3-methylbenzyl)-8-((4-(thiazol-2-yl)piperazin-l-yl)methyl)-lH-purine- 2,6(3H,7H)-dione (28 mg, 0.057 mmol, 57.1 % yield). H NMR (400 MHz, Chloroform-if) δ 7.23 - 7.16 (m, 2H), 7.09 (d, = 7.8 Hz, 1H), 6.96 - 6.88 (m, 2H), 6.59 (d, = 3.7 Hz, 1H), 5.76 (s, 2H), 3.60 (d, = 4.2 Hz, 5H), 3.47 (s, 4H), 3.42 (d, = 1.3 Hz, 3H), 2.57 (s, 4H), 2.31 (d, = 4.3 Hz, 3H); MS (M+H)+= 466. |
[ 104481-24-5 ]
Ethyl 2-piperazin-1-yl-thiazole-4-carboxylate
Similarity: 0.58
[ 90586-84-8 ]
N-Ethylthiazol-2-amine hydrochloride
Similarity: 0.90
[ 170492-30-5 ]
2-Morpholinothiazol-4-amine hydrochloride
Similarity: 0.69
[ 848841-68-9 ]
4-(4-Chlorothiazol-2-yl)morpholine
Similarity: 0.67